跳至主要内容
临床试验/NCT01252836
NCT01252836撤回4 期

Randomized, Prospective, Pilot Study Evaluating a Temporary Skin Substitute (AWBAT-D) Versus the Standard of Care in the Postoperative Treatment of Split-thickness Skin Graft Donor Sites

Georgetown University1 个研究点 分布在 1 个国家开始时间: 2010年9月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
撤回
试验地点
1
主要终点
Time for donor site to heal with AWBAT-D

研究概览

简要总结

Use of AWBAT-D on split thickness skin graft sites will reduce healing time and pain level.

详细描述

The study is designed as a randomized-controlled trial to examine split thickness skin graft donor wound site healing using AWBAT-D compared to current standard of care: Tegaderm. This will involve randomizing subjects to treatment with the AWBAT-D dressing or Tegaderm and monitoring outcomes. The AWBAT-D device has collagen and we hypothesize that the wounds treated with it will heal faster and with a decreased pain level. The purpose of this study is to evaluate if there are differences in outcomes between AWBAT-D and Tegaderm in healing split thickness skin graft donor sites.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
是

入选标准

  • •Subject is 18 years of age or older
  • •Subjects requiring a split-thickness skin graft with a wound size between 5 and 50cm2 and a depth between 12-18um.
  • •Ability and willingness to understand and comply with study procedures and to give written informed consent prior to enrollment in the study.

排除标准

  • •Subjects < 18 years of age
  • •Subjects with an allergy to porcine products.
  • •Subjects undergoing STSG with a wound size less than 5 cm2 or greater than 50cm
  • •Subjects undergoing STSG with a wound depth of less than 12um or greater than 18um.
  • •Subjects undergoing repeat skin graft harvesting at the same donor site.
  • •Has active malignant disease of any kind. A subject, who has had a malignant disease in the past, was treated and is currently disease-free, may be considered for study entry.
  • •Subjects participating in any other trials involving the split-thickness skin graft donor site.

研究组 & 干预措施

AWBAT-D

Experimental

Application of AWBAT-D on donor site.

干预措施: AWBAT-D (Device)

Control

Placebo Comparator

Treatment with Tegaderm

干预措施: AWBAT-D (Device)

结局指标

主要结局

Time for donor site to heal with AWBAT-D

时间窗: 6 weeks

As compared to current standard of care, Tegaderm.

次要结局

  • Pain at donor site(6 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Christopher Attinger, M.D.

Director of Center for Wound Healing

Georgetown University

研究点 (1)

Loading locations...

相似试验